Your browser doesn't support javascript.
loading
Smoldering multiple myeloma: the role of different scoring systems in identifying high-risk patients in real-life practice.
Cocito, Federica; Mangiacavalli, Silvia; Ferretti, Virginia Valeria; Cartia, Claudio Salvatore; Ganzetti, Maya; Benveuti, Pietro; Pompa, Alessandra; Catalano, Martina; Fugazza, Elena; Landini, Benedetta; Arcaini, Luca; Corso, Alessandro.
Afiliación
  • Cocito F; Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  • Mangiacavalli S; Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  • Ferretti VV; Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  • Cartia CS; University of Pavia, Pavia, Italy.
  • Ganzetti M; Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  • Benveuti P; Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  • Pompa A; University of Pavia, Pavia, Italy.
  • Catalano M; Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  • Fugazza E; University of Pavia, Pavia, Italy.
  • Landini B; Hematology, Fondazione IRCCS Ca' Granda Ospedale Maggiore di Milano Policlinico, Milano, Italy.
  • Arcaini L; University of Pavia, Pavia, Italy.
  • Corso A; Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Leuk Lymphoma ; 60(12): 2968-2974, 2019 12.
Article en En | MEDLINE | ID: mdl-31169049
ABSTRACT
We explore the predictive role of 2014-updated International Myeloma Working Group (IMWG) diagnostic criteria and of some of currently available risk models for progression to symptomatic myeloma when applied in our unselected population of 75 smoldering multiple myeloma (SMM) patients observed between 2000 and 2015. Risk scores including routinely used clinical parameters such as bone marrow plasmacell infiltration rate, immunoparesis, serum monoclonal component (sMC) value, and altered free light chain ratio (FLCr), were clinically useful to identify SMM patients at higher risk of progression. Time to myeloma progression in our ultra-high risk SMM according to IMWG diagnostic update criteria was very short (12.4 months). Our analysis identified as independent reliable predictors of progression altered FLCr as well as increasing plasma cell infiltration which are part of most commonly applied risk models. Waiting for new scoring systems, bone marrow evaluation and complete laboratory screening are still milestones for SMM management.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Medición de Riesgo / Mieloma Múltiple Quiescente Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Leuk Lymphoma Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2019 Tipo del documento: Article País de afiliación: Italia Pais de publicación: EEUU / ESTADOS UNIDOS / ESTADOS UNIDOS DA AMERICA / EUA / UNITED STATES / UNITED STATES OF AMERICA / US / USA

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Medición de Riesgo / Mieloma Múltiple Quiescente Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Leuk Lymphoma Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2019 Tipo del documento: Article País de afiliación: Italia Pais de publicación: EEUU / ESTADOS UNIDOS / ESTADOS UNIDOS DA AMERICA / EUA / UNITED STATES / UNITED STATES OF AMERICA / US / USA